Guardant Health, Inc. (GH)
NASDAQ: GH · IEX Real-Time Price · USD
17.16
-0.94 (-5.19%)
At close: Apr 25, 2024, 4:00 PM
17.20
+0.04 (0.23%)
After-hours: Apr 25, 2024, 4:55 PM EDT
Guardant Health Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Guardant Health stock have an average target of 39.2, with a low estimate of 27 and a high estimate of 55. The average target predicts an increase of 128.44% from the current stock price of 17.16.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for GH stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 4 |
| Buy | 10 | 10 | 9 | 6 | 6 | 6 |
| Hold | 0 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 16 | 15 | 11 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +63.17% | Apr 24, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $32 → $28 | Strong Buy | Maintains | $32 → $28 | +63.17% | Apr 15, 2024 |
| Guggenheim | Guggenheim | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 5, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $40 → $30 | Buy | Maintains | $40 → $30 | +74.83% | Feb 26, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $60 → $45 | Buy | Maintains | $60 → $45 | +162.24% | Feb 23, 2024 |
Financial Forecast
Revenue This Year
683.98M
from 563.95M
Increased by 21.28%
Revenue Next Year
832.34M
from 683.98M
Increased by 21.69%
EPS This Year
-3.25
from -4.28
EPS Next Year
-2.95
from -3.25
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 709.8M | 913.4M | 1.2B | 1.5B | 2.1B |
| Avg | 684.0M | 832.3M | 1.0B | 1.4B | 1.9B |
| Low | 645.4M | 745.4M | 869.1M | 1.2B | 1.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 25.9% | 33.5% | 40.8% | 41.7% | 48.4% |
| Avg | 21.3% | 21.7% | 24.5% | 34.1% | 35.0% |
| Low | 14.4% | 9.0% | 4.4% | 19.7% | 20.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.63 | -1.94 | -0.83 | -0.57 | 0.83 |
| Avg | -3.25 | -2.95 | -2.45 | -0.56 | 0.81 |
| Low | -3.73 | -3.41 | -3.74 | -0.53 | 0.77 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.